close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

11.72 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,013
Open 11.72
Bid (Size) 11.74 (2,100)
Ask (Size) 13.50 (100)
Prev. Close 11.72
Today's Range 11.72 - 11.72
52wk Range 6.370 - 25.77
Shares Outstanding 49,383,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-23.4%
-23.4%
1 Month
-19.5%
-19.5%
3 Month
-45.9%
-45.9%
6 Month
-25.2%
-25.2%
1 Year
+77.0%
+77.0%

More News

Read More
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics (NASDAQ:GLUE) Beats Q2 Revenue Estimates but Posts Wider Loss ↗
Via Chartmill
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts ↗
Via Chartmill
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗
Via Stocktwits
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher ↗
Via MarketBeat
Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD, GLUE Are On Traders' Radar Today ↗
Via Stocktwits
Topics Government Stocks
News headline image
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?
Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?
Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?
The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market
What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?
The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 11.72
When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?
The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 09/24/26 04:00 PM ET
What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?
The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 578.78M
How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?
Monte Rosa Therapeutics, Inc. - Common Stock has 579M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.